Immunodeficiency in Children Starting Antiretroviral Therapy in Low-, Middle-, and High-Income Countries
Authors:
- Manuel KollerMKManuel Koller
- Valeriane LeroyVLValeriane Leroy
- 1 January 2015
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 68 (1) , 62-72
Abstract
Background: The CD4 cell count or percent (CD4%) at the start of combination antiretroviral therapy (cART) is an important prognostic factor in children starting therapy and an important indicator of program performance. We describe trends and determinants of CD4 measures at cART initiation in children from low-, middle-, and high-income countries. Methods: We included children aged <16 years from clinics participating in a collaborative study spanning sub-Saharan Africa, Asia, Latin America, and the United States. Missing CD4 values at cART start were estimated through multiple imputation. Severe immunodeficiency was defined according to World Health Organization criteria. Analyses used generalized additive mixed models adjusted for age, country, and calendar year. Results: A total of 34,706 children from 9 low-income, 6 lower middle-income, 4 upper middle-income countries, and 1 high-income country (United States) were included; 20,624 children (59%) had severe immunodeficiency. In low-income countries, the estimated prevalence of children starting cART with severe immunodeficiency declined from 76% in 2004 to 63% in 2010. Corresponding figures for lower middle-income countries were from 77% to 66% and for upper middle-income countries from 75% to 58%. In the United States, the percentage decreased from 42% to 19% during the period 1996 to 2006. In low- and middle-income countries, infants and children aged 12–15 years had the highest prevalence of severe immunodeficiency at cART initiation. Conclusions: Despite progress in most low- and middle-income countries, many children continue to start cART with severe immunodeficiency. Early diagnosis and treatment of HIV-infected children to prevent morbidity and mortality associated with immunodeficiency must remain a global public health priority.Keywords
This publication has 29 references indexed in Scilit:
- Prognosis of Children With HIV-1 Infection Starting Antiretroviral Therapy in Southern AfricaThe Pediatric Infectious Disease Journal, 2014
- Task Shifting for the Delivery of Pediatric Antiretroviral TreatmentJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescentsAIDS, 2009
- Universal HIV testing of infants at immunization clinics: an acceptable and feasible approach for early infant diagnosis in high HIV prevalence settingsAIDS, 2009
- Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan AfricaThe Lancet Infectious Diseases, 2008
- Clinical Outcomes and CD4 Cell Response in Children Receiving Antiretroviral Therapy at Primary Health Care Facilities in ZambiaJAMA, 2007
- Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programmeInternational Journal of Epidemiology, 2007
- Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)International Journal of Epidemiology, 2007
- Polymerase Chain Reaction for Diagnosis of Human Immunodeficiency Virus Infection in Infancy in Low Resource SettingsThe Pediatric Infectious Disease Journal, 2005
- The TREAT Asia HIV Observational DatabaseJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005